187 related articles for article (PubMed ID: 21935756)
1. Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement.
Yoshida K; Wada H; Hasegawa M; Wakabayashi H; Ando H; Oshima S; Matsumoto T; Shimokariya Y; Noma K; Yamada N; Uchida A; Nobori T; Sudo A
Int J Hematol; 2011 Oct; 94(4):355-360. PubMed ID: 21935756
[TBL] [Abstract][Full Text] [Related]
2. Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.
Yoshida K; Wada H; Hasegawa M; Wakabayashi H; Matsumoto T; Shimokariya Y; Noma K; Yamada N; Uchida A; Nobori T; Sudo A
Int J Hematol; 2012 Feb; 95(2):160-6. PubMed ID: 22270404
[TBL] [Abstract][Full Text] [Related]
3. The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery.
Hasegawa M; Wada H; Wakabayashi H; Yoshida K; Miyamoto N; Asanuma K; Matsumoto T; Ohishi K; Shimokariya Y; Yamada N; Uchida A; Sudo A
Clin Chim Acta; 2013 Oct; 425():109-13. PubMed ID: 23876378
[TBL] [Abstract][Full Text] [Related]
4. The influence of fondaparinux on the diagnosis of postoperative deep vein thrombosis by soluble fibrin and D-dimer.
Niimi R; Hasegawa M; Shi DQ; Sudo A
Thromb Res; 2012 Nov; 130(5):759-64. PubMed ID: 22192153
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux.
Ikejiri M; Wada H; Yamaguchi T; Miyazaki S; Hasegawa M; Wakabayashi H; Asanuma K; Sakaguchi A; Matsumoto T; Ohishi K; Fujimoto N; Yamada N; Ito M; Katayama N; Sudo A
Int J Hematol; 2016 May; 103(5):554-9. PubMed ID: 26922193
[TBL] [Abstract][Full Text] [Related]
6. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
[TBL] [Abstract][Full Text] [Related]
7. Assessment of an Extended Interval Fondaparinux Dosing Regimen for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Severe Renal Dysfunction Using Antifactor Xa Levels.
Wahby KA; Riley LK; Tennenberg SD
Pharmacotherapy; 2017 Oct; 37(10):1241-1248. PubMed ID: 28833353
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
Lu X; Lin J
BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
[TBL] [Abstract][Full Text] [Related]
10. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
11. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
12. Incidence and time course of asymptomatic deep vein thrombosis with fondaparinux in patients undergoing total joint arthroplasty.
Yamaguchi T; Hasegawa M; Niimi R; Sudo A
Thromb Res; 2010 Oct; 126(4):e323-6. PubMed ID: 20451962
[TBL] [Abstract][Full Text] [Related]
13. Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty.
Yukizawa Y; Inaba Y; Watanabe S; Yajima S; Kobayashi N; Ishida T; Iwamoto N; Hyonmin C; Nakamura M; Saito T
J Thromb Thrombolysis; 2012 Nov; 34(4):526-32. PubMed ID: 22802080
[TBL] [Abstract][Full Text] [Related]
14. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
Reynolds NA; Perry CM; Scott LJ
Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
[TBL] [Abstract][Full Text] [Related]
15. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
[TBL] [Abstract][Full Text] [Related]
17. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
[TBL] [Abstract][Full Text] [Related]
18. Fondaparinux: a new antithrombotic agent.
Cheng JW
Clin Ther; 2002 Nov; 24(11):1757-69; discussion 1719. PubMed ID: 12501872
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis against venous thromboembolism in orthopedic surgery.
Liu LT; Ma BT
Chin J Traumatol; 2006 Aug; 9(4):249-56. PubMed ID: 16849000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
